Glycotope Reported Promising First-in-Man Data of Novel Glyco-Optimised Monoclonal Anti-TA-MUC1 Antibody PankoMab-GEX
Glycotope GmbH, a global leader in optimising the sugar chains (glycosylation) of biopharmaceuticals, has announced full details of its first-in-man Phase I trial for PankoMab-GEXTM at this year's European Cancer Congress (ECCO 17). PankoMab-GEX is a potent humanised and glycoengineered antibody with respect to its specificity and anti-tumour activity recognising the novel tumour-specific epitope TA-MUC1 expressed in the majority of solid cancer indications and patients and virtually absent on normal cells.
In conclusion, PankoMab-GEX clearly demonstrated clinical activity as single agent in heavily pretreated progressive patients with far advanced cancers and could be safely administered at all tested doses and schedules with a very favorable safety, side-effect and pharmacokinetic profile.
In the open label Phase I dose escalation study (3+3 design), 74 patients with TA-MUC1-positive advanced solid tumours, all progressing after standard treatments, were treated with various doses of PankoMab-GEX from 1 to 2200 mg with three dosing schedules (once every three weeks, once every two weeks and weekly). The primary objective of the study was to evaluate the safety and tolerability profile of this novel compound and to define the recommended Phase II dosing regimen. Secondary endpoints included pharmacokinetics, immunogenicity and object-tumour response.
Activity was seen over all dose levels, with a clinical benefit rate of 50% at dose levels of >= 600 mg (19/34). One complete response in ovarian cancer for 485 days and one partial response for 295 days in non-small cell lung cancer (NSCLC) were observed (RECIST 1.1). The other patients showed continuing sustained clinical benefit in various cancers with an average duration of >240 days and the longest duration of 25 months (patient with pseudomyxoma peritonei with >20% tumour reduction). In the subgroup of ovarian cancer patients the clinical benefit rate at dose levels of >= 600 mg was 60% (9/15) including one complete responder. Progressive ovarian cancer patients previously sensitive or resistant to their last platinum therapy, regardless of additional refractory treatments, showed clinical benefit in all platinum sensitive (5/5) and in most resistant (3/5) patients. One patient refractory to platinum (1/5) showed an extended clinical benefit. NSCLC patients, albeit only treated with lower doses of PankoMab-GEX, showed in four of seven patients a clinical benefit including one partial responder.
PankoMab-GEX showed a very favorable side-effect profile with mild to moderate adverse events, mainly infusion related reactions during the first infusion. No maximum tolerated dose was reached. As expected because its high specificity, pharmacokinetics were linear over all doses with a long half-life allowing administration schedules once every three weeks or shorter.
Steffen Goletz, CEO, CSO and Founder of Glycotope, commented: "We are very pleased with these data. PankoMab-GEX has shown an excellent safety profile at all dose levels and promising efficacy results in heavily pretreated cancer patients already as a single agent. Because of its high specificity and long duration of action, PankoMab-GEX is a highly attractive option for the future treatment of various solid tumors and will be further developed in Phase II trials."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance